ESC 365 - Effects of the PAR-1 receptor antagonist vorapaxar on platelet activation and coagulation biomarkers in patients with stable coronary artery disease

ESC Premium Access

Effects of the PAR-1 receptor antagonist vorapaxar on platelet activation and coagulation biomarkers in patients with stable coronary artery disease

Session: Innovative drug therapies

Topic: Antiplatelet Drugs

Speaker: Mrs R. Olie (Maastricht, NL)

Event: ESC Congress 2018

Congress Presentation

Add to my library

About the speaker

Mrs Renske Olie

Maastricht University Medical Centre (MUMC), Maastricht (Netherlands (The))

0 follower

8 more presentations in this session

Six-month treatment with novel oral anticoagulants ameliorates cerebral blood flow, as evaluated with brain perfusion SPECT.

Speaker: Doctor H. Takeuchi (Ogachi, JP)

TAFI level dynamics during long-term warfarin therapy as a predictor of recurrent bleedings in a target INR

Speaker: Professor N. Vorobyeva (Moscow, RU)

Pharmacokinetics and pharmacodynamics of alirocumab in patients with autosomal dominant hypercholesterolemia associated with PCSK9 gain-of-function or ApoB loss-of-function mutations

Speaker: Doctor M. Krempf (Nantes, FR)

Evaluation of the pharmacokinetics and pharmacodynamics of subcutaneously administered dutogliptin for daily injection with granulocyte colony stimulating factor (G-CSF) for AMI

Speaker: Mr D. Nix (Lexington Township, US)

Multiple ascending doses of recombinant human lecithin-cholesterol acyltransferase in patients with atherosclerosis: phase 2a primary results

Speaker: Doctor M. Bonaca (Aurora, US)

Access the full session

Innovative drug therapies

Speakers: Mrs R. Olie, Doctor H. Takeuchi, Professor N. Vorobyeva, Doctor M. Krempf, Mr D. Nix...

About the event

ESC Congress 2018

25 August - 29 August 2018

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources